budiodarone

Budiodarone is a small molecule antiarrhythmic agent and a chemical analog of amiodarone, designed to maintain the efficacy of amiodarone while reducing its adverse side effects. It features an ester modification (sec-butyl acetate side chain) that allows for rapid metabolism by plasma and tissue esterases, resulting in a much shorter half-life (about 7 hours) compared to amiodarone (35–68 days). Budiodarone exhibits mixed cardiac ion channel blocking activity, affecting multiple channels and thus displaying properties of all four Vaughan Williams antiarrhythmic classes. It is being developed primarily for the long-term management of symptomatic non-permanent atrial fibrillation (AFib), including paroxysmal and persistent forms. Clinical trials have shown dose-dependent reductions in AF burden without the significant hepatic, pulmonary, or thyroid toxicities associated with amiodarone. The drug is administered orally as a tartrate salt[1][2][3][4][5][7].

Other names

budiodarone tartrate